Literature DB >> 10807502

A major metabolite of aceclofenac, 4'-hydroxy aceclofenac, suppresses the production of interstitial pro-collagenase/proMMP-1 and pro-stromelysin-1/proMMP-3 by human rheumatoid synovial cells.

R Yamazaki1, S Kawai, Y Mizushima, T Matsuzaki, S Hashimoto, T Yokokura, A Ito.   

Abstract

OBJECTIVE AND
DESIGN: We examined the effects of aceclofenac and its metabolites on the production of pro-collagenase-1/pro-matrix metalloproteinase-1 (proMMP-1), pro-gelatinase A/proMMP-2, pro-stromelysin-1/proMMP-3 and tissue inhibitor of metalloproteinases-1 (TIMP-1) by rheumatoid synovial cells. MATERIALS: Synovial cells were obtained from patients with rheumatoid arthritis. TREATMENT: Cultures of confluent cells were treated with interleukin-1beta (IL-1beta)(1 ng/ml) and/or test drugs (0.3-30 microM) for 48 h.
METHODS: Production of proMMPs and TIMP-1 was monitored by Western blotting or gelatin zymography. Prostaglandin E2 (PGE2) was measured by an enzyme immunoassay.
RESULTS: 4'-Hydroxy aceclofenac, a major metabolite of aceclofenac, down-regulated both basal and IL-1beta-induced production of proMMP-1 and proMMP-3 at a concentration sufficient to suppress PGE2 production without modulating proMMP-2 or TIMP-1, whereas aceclofenac itself had no marked effect on the production of proMMPs.
CONCLUSIONS: Down-regulation of proMMP-1 and proMMP-3 production by 4'-hydroxy aceclofenac may contribute to the therapeutic effect of aceclofenac on rheumatoid arthritis and osteoarthritis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10807502     DOI: 10.1007/s000110050571

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  3 in total

1.  Pharmacokinetics of a new once-daily controlled-release formulation of aceclofenac in Korean healthy subjects compared with immediate-release aceclofenac and the effect of food: a randomized, open-label, three-period, crossover, single-centre study.

Authors:  Soo Kyung Bae; Soo-Hwan Kim; Hae Won Lee; Sook Jin Seong; Su-Yeon Shin; Sang Hun Lee; Mi-Sun Lim; Young-Ran Yoon; Hye Jung Lee
Journal:  Clin Drug Investig       Date:  2012-02-01       Impact factor: 2.859

Review 2.  Aceclofenac: a reappraisal of its use in the management of pain and rheumatic disease.

Authors:  M Dooley; C M Spencer; C J Dunn
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 3.  Extracellular matrix degradation and tissue remodeling in periprosthetic loosening and osteolysis: focus on matrix metalloproteinases, their endogenous tissue inhibitors, and the proteasome.

Authors:  Spyros A Syggelos; Alexios J Aletras; Ioanna Smirlaki; Spyros S Skandalis
Journal:  Biomed Res Int       Date:  2013-06-19       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.